Atorvastatin Prevented and Reversed Dexamethasone-Induced Hypertension in the Rat

References

• Li M, Fraser T, Wang J, Whitworth JA. Dexamethasone-induced hypertension in the rat: effects of L-arginine. Clin Exp Pharmacol Physiol 1997; 24: 730–732, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KU, Whitworth JA. The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2004; 17: 260–265, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levine G, Keaney J, Vital J. Cholesterol reduction in cardiovascular disease. N Eng J Med 1995; 332: 512–521, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711–2719, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300–305, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002; 40: 611–617, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450–1457, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135–141, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001; 37: 781–786, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schnackenberg C, Wilcox C. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso-prostaglandin F2a. Hypertension 1999; 33: 424–428, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44: 186–190, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41: 892–896, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adrenocortical steroid hypertension: a historical perspective. The adrenal and hypertension: from cloning to clinic. Serono symposia, F Mantero, R Takeda, BA Scoggins, EG Biglieri, JW Funder. Raven Press, New York 1989; 177–190
   Google Scholar
• Turner SW, Wen C, Li M, Fraser TB, Whitworth JA. Adrenocorticotrophin dose-response relationships in the rat: haemodynamic, metabolic and hormonal effects. J Hypertens 1998; 16: 593–600, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wen C, Li M, Fraser T, Wang J, Turner SW, Whitworth JA. L-arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. Blood Press 2000; 9: 298–304, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Turner SW, Wen C, Li M, Whitworth JA. L-arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996; 27: 184–189, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Glucocorticoid biology—a historical perspective. Glucocorticoids (milestones in drug therapy)1st, NJ Goulding, RJ Flower. Birkhäuser Verlag, Basal 2001; 18
   Google Scholar
• Whitworth JA, Gordon D, McLachlan-Troup N, Scoggins BA, Moulds RW. Dexamethasone suppression in essential hypertension: effects on cortisol and blood pressure. Clin Exp Hypertens 1989; 11: 323–335, [CSA]
   Web of Science ®Google Scholar
• Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996; 27: 190–196, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke—comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004; 9: 1–17, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tayek J. Atorvastatin reduced coronary and stroke events in patients with hypertension and without dyslipidemia. ACP J Club 2004; 140: A16, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Croom KF, Plosker GL. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005; 65: 137–152, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64(Suppl 2)43–60, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu L, Cheng L, Zhang P. [Expression of plasma ROS, SOD, and GSH-PX in patients with nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2003; 17: 650–651, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Zhou SG, Xu LP, Liao DF, Lei XY, Yan FX, Zhu BY. Cyclosporin A inhibits the adhesion of neutrophil with ECV-304 induced by hypoxia/reoxygenation via ROS-Cyclophilin A-ERK1/2 pathway. Sheng Li Xue Bao 2004; 56: 313–320, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767–775, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Menschikowski M, Hagelgans A, Heyne B, Hempel U, Neumeister V, Goez P, et al. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 2005; 1733: 157–171, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 2005; 280: 6627–6633, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the rho-kinase pathway. Biochem Biophys Res Commun 2004; 320: 34–38, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar